Summary of Key Utility Parameter Estimates in Studies Cited in the Systematic Review
| Author | QoL Source | PF Utility | PD Utility | Pulmonary Disutility | Diarrhea Disutility | Endocrine Disutility |
|---|---|---|---|---|---|---|
| Ward | CheckMate 141 EQ-5D QLQ-C30 QLQ-H&N 35 | 0.680 | 0.660 | NR | NR | NR |
| Zagar | CheckMate 141 | NR | NR | −0.200 IO | −0.207 IO | −0.210 IO |
| Tringale | CheckMate 141 | 0.517 | 0.280 | NR | NR | NR |
| Goeree | CheckMate 017 EQ-5D | 0.789 | 0.674 | -0.008 | NR | NR |
| Matter Walstra | Literature | 0.756 | 0.470 | NR | NR | NR |
| Aguilar | Literature | 0.65 | 0.43 | NR | NR | NR |
| Huang | KEYNOTE 010 EQ-5D | 0.761 | 0.687 | −0.09 | NR | NR |
| Huang | KEYNOTE 024 EQ-5D | NR | NR | NR | NR | NR |
| Wan | CheckMate 025 EQ-5D | 0.848 | 0.68 | NR | NR | NR |
| McCrea | CheckMate 025 EQ-5D | Re 0.895SD 0.846 | 0.817 | NR | NR | NR |
| Sarfaty | CheckMate 025 FKSI-DRS | 0.89 | 0.78 | NR | NR | NR |
| Sarfaty | NR | NR | NR | NR | NR | NR |
| Barzey | MDX010–20 SF-36 | CR 0.88SD 0.80 | 0.52 | NR | NR | NR |
| Curl | Literature and Expert Opinion | Re 0.88SD 0.80 | 0.52 | NR | −0.09 | NR |
| Bohensky | CA209066 EQ-5D | 0.828 | 0.798 | NR | NR | NR |
| Oh | CheckMate 067 | 0.667 | 0.433 | −0.159 IO | − 0.116 IO | − 0.115 IO |
| Wang | KEYNOTE 006 EQ-5D | 0.83–0.86 | 0.78 | NR | NR | NR |
| Miguel | KEYNOTE 006 EQ-5D | 0.80 | 0.70 | NR | NR | NR |
| Kohn | Literature | Re 0.88SD first line therapy 0.80 | 0.52 | −0.17 IO | −0.17 IO | − 0.17 IO |
| Meng | CheckMate 066 EQ-5D | 0.78–0.80 | 0.71–0.73 | NR | NR | NR |
Note: Utility and disutility values used by the systematic review studies
QoL quality of life, PF progression free, PD progressive disease, IO immune-oncology specific, NR not reported, Re response, SD stable disease, CR complete response